KAREN RABIN to Case-Control Studies
This is a "connection" page, showing publications KAREN RABIN has written about Case-Control Studies.
Connection Strength
0.215
-
Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS. Genet Epidemiol. 2025 Jun; 49(4):e70010.
Score: 0.035
-
Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes. JCO Clin Cancer Inform. 2025 May; 9:e2400223.
Score: 0.035
-
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
Score: 0.033
-
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
Score: 0.025
-
Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. J Natl Cancer Inst. 2019 12 01; 111(12):1350-1357.
Score: 0.024
-
Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
Score: 0.023
-
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
Score: 0.022
-
The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
Score: 0.018